Lannett Company, Inc.  

(Public, NYSE:LCI)   Watch this stock  
Find more results for Migraine
20.00
+0.20 (1.01%)
Real-time:   12:37PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 19.95 - 20.20
52 week 16.75 - 39.99
Open 20.05
Vol / Avg. 91,418.00/843,915.00
Mkt cap 731.68M
P/E     -
Div/yield     -
EPS -0.09
Shares 37.23M
Beta 2.43
Inst. own 98%
Aug 21, 2017
Q4 2017 Lannett Company Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 31, 2017
Lannett Company Inc at Craig-Hallum Institutional Investor Conference Add to calendar
May 16, 2017
Lannett Company Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 4, 2017
Lannett Company Inc at Deutsche Bank Health Care Conference - Webcast
May 2, 2017
Q3 2017 Lannett Company Inc Earnings Call - Webcast
May 2, 2017
Q3 2017 Lannett Company Inc Earnings Release
Mar 21, 2017
Lannett Company Inc at Oppenheimer Healthcare Conference - Webcast
Mar 13, 2017
Lannett Company Inc at ROTH Conference - Webcast
Mar 6, 2017
Lannett Company Inc at Raymond James Institutional Investors Conference
Mar 2, 2017
Lannett Company Inc at Deutsche Bank Pharma One-on-One Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 9.01% 7.92%
Operating margin 26.33% 22.57%
EBITD margin - 40.66%
Return on average assets 3.54% 3.95%
Return on average equity 10.98% 8.80%
Employees 1,149 -
CDP Score - -

Address

9000 State Rd
PHILADELPHIA, PA 19136-1615
United States - Map
+1-215-3339000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Officers and directors

Jeffrey Farber Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Arthur P. Bedrosian J.D. Chief Executive Officer, Director
Age: 70
Bio & Compensation  - Reuters
Martin P. Galvan CPA Chief Financial Officer, Vice President - Finance, Treasurer
Age: 64
Bio & Compensation  - Reuters
Robert Ehlinger Vice President - Logistics, Chief Information Officer
Age: 59
Bio & Compensation  - Reuters
Kevin R. Smith Vice President - Sales and Marketing
Age: 56
Bio & Compensation  - Reuters
John M. Abt Vice President of Quality
Age: 51
Bio & Compensation  - Reuters
Kristin A. Arnold Vice President - Research and Development
Bio & Compensation  - Reuters
David Drabik Lead Independent Director
Age: 48
Bio & Compensation  - Reuters
James M. Maher Independent Director
Age: 64
Bio & Compensation  - Reuters
Albert Paonessa III Independent Director
Age: 55
Bio & Compensation  - Reuters